Keep an eye on rebounding shares of Viking Therapeutics (VKTX).

Earlier this year, the company reported that the injectable form of its obesity treatment helped patients lose up to 13.1% of their weight after 13 weeks. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials. 

Helping, Goldman Sachs just raised its obesity drug market estimate to $130 billion from $100 billion. All on the belief that about 19 million Americans could be on anti-obesity drugs by 2030, up from a prior estimate of 15 million.

Even better, Viking is turning heads with its potential treatment for non-alcoholic steatohepatitis, or NASH. In a recent Phase 2b VOYAGE study of its VK2809 treatment in patients with biopsy-confirmed non-alcoholic steatohepatitis, the company “achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo.”

Waiting on further positive developments, we’d use weakness as an opportunity with VKTX.